ARQT
Arcutis Biotherapeutics, Inc.
ARQT's fundamentals are strong: revenue grew 60% and its operating margin went from −12% to 6.9%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ARQT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Weak |
ARQT's revenue, profitability and cash flow are currently healthy, but its balance sheet is weak.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ARQT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 41x | $27.53 | — |
| Cheap | 110x | $24.27 | -12% |
| Fair | 116x | $25.54 | -7.2% |
| Current | 125x | $27.53 | — |
| Expensive | 129x | $28.33 | +2.9% |
Historical ranges are pointers, not guarantees.
ARQT's PE is 125x, but its earnings don't support one, so it isn't a reliable read right now.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ARQT Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
ARQT has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ARQT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.67 | +206% |
| Q3 2026 | $0.22 | +$0.58 |
| Q2 2026 | $0.22 | +$0.97 |
| Q1 2026 | -$0.02 | +$1.02 |
| Q4 2025 | -$0.13 | +$1.03 |
| Q3 2025 | -$0.36 | +$1.29 |
| Q2 2025 | -$0.75 | +$1.30 |
| Q1 2025 | -$1.04 | +$1.75 |
| Q4 2024 | -$1.16 | +$2.62 |
ARQT has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ARQT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $143.9M | +45% |
| Q2 2026 | $129.9M | +59% |
| Q1 2026 | $105.4M | +60% |
| Q4 2025 | $129.5M | +81% |
| Q3 2025 | $99.2M | +122% |
| Q2 2025 | $81.5M | +164% |
| Q1 2025 | $65.8M | +33% |
| Q4 2024 | $71.4M | +428% |
ARQT has the edge over HIMS on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 6.6% | -2 points |
| Q2 2026 | 13% | +31 points |
| Q1 2026 | -8.6% | +29 points |
| Q4 2025 | 14% | +25 points |
| Q3 2025 | 8.6% | +96 points |
| Q2 2025 | -18% | +144 points |
| Q1 2025 | -37% | +27 points |
| Q4 2024 | -11% | +442 points |
ARQT has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
ARQT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $18.8M | +$20.6M |
| Q2 2026 | $12.5M | +4974% |
| Q1 2026 | $2.2M | +$33.2M |
| Q4 2025 | $26.2M | +$26.9M |
| Q3 2025 | -$1.8M | +$33.1M |
| Q2 2025 | $246K | +$45.4M |
| Q1 2025 | -$31M | +$615K |
| Q4 2024 | -$748K | +$55.5M |
ARQT has the edge over HIMS on cash flow, with more consistent year-over-year improvement.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
ARQT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.7% | +938K shares |
| 1 year | +7.7% | +9.8M shares |
| 3 years | +124% | +75.7M shares |
| 5 years | +189% | +89.6M shares |
| Available history | +259% | +98.7M shares |
ARQT has 137M diluted shares, up 7.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ARQT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ARQT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2024 | 12.5x | High |
| Q1 2024 | 0.1x | Very low |
| Q4 2023 | 0.8x | Very low |
| Q3 2023 | 0.7x | Very low |
ARQT's net debt is about 13 years of its operating earnings (EBITDA).
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ARQT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 53.0 | Neutral |
| Stochastic | 48.9 | Neutral |
ARQT's weekly RSI is 53 (neutral) and its Stochastic is 49 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ARQT PE vs Healthcare Sector
| Metric | ARQT | Sector median | Relative |
|---|---|---|---|
| PE | 125x | 26x | 384% above |
ARQT is trading at 125x earnings, a 384% premium to the Healthcare sector's median of 26x, though its earnings don't support one.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ARQT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $28.0 | 1.6% below |
| 20 week MA | $26.7 | 3.2% above |
| 50 week MA | $25.7 | 7.2% above |
| 100 week MA | $21.0 | 31% above |
| 200 week MA | $15.0 | 84% above |
ARQT has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ARQT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $21.8 | $29.6 | +36% |
| 2021 | $29.6 | $20.1 | -32% |
| 2022 | $20.1 | $14.3 | -29% |
| 2023 | $14.3 | $3.23 | -77% |
| 2024 | $3.23 | $14.3 | +343% |
| 2025 | $14.3 | $29.0 | +103% |
| 2026 YTD | $29.0 | $27.5 | -5% |
ARQT has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.